• Explore /
  • Poster
  • / Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer.

Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer.

Abstract Video & Slides Poster

Authors

Mohamed Bouattour

Mohamed Bouattour

Department of Liver Cancer Unit, Assistance Publique–Hôpitaux de Paris Hôpital Beaujon, Paris, France;

Mohamed Bouattour , Juan W. Valle , Arndt Vogel , Jin Won Kim , Masayuki Kitano , Jen-Shi Chen , Howard A. Burris III , Renata Zaucha , Shukui Qin , Ludovic Evesque , David Bing Zhen , Vineet Govinda Gupta , Joon Oh Park , Magdalena Żotkiewicz , Nana Rokutanda , Gordon Cohen , Do-Youn Oh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03875235

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 531)

DOI

10.1200/JCO.2023.41.4_suppl.531

Abstract #

531

Poster Bd #

C1

Abstract Disclosures

Similar Posters

First Author: Aiwu He

First Author: John Ebben

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Prognostic effects of co-occurring <i>TP53</i> and <i>KRAS</i> aberrations in patients with advanced biliary tract cancer.

Prognostic effects of co-occurring TP53 and KRAS aberrations in patients with advanced biliary tract cancer.

First Author: Taro Shibuki

First Author: Osama Aqel